<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Syphilis in patients with HIV
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Syphilis in patients with HIV
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Syphilis in patients with HIV
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Anne Rompalo, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jeanne Marrazzo, MD, MPH, FACP, FIDSA
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jennifer Mitty, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 17, 2019.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Syphilis is a sexually acquired infection, which, if left untreated, is characterized by episodes of active clinical disease interrupted by periods of latent (asymptomatic) infection. Some studies suggest that HIV infection may modulate the clinical presentation of syphilis (eg, greater organ involvement, atypical and florid skin rashes, more rapid progression to neurosyphilis), as well as the clinical and serologic response to syphilis treatment. Syphilis may also have a negative impact on the HIV viral load.
        </p>
        <p>
         This topic will review the epidemiology, clinical presentation, diagnosis, and treatment of syphilis in patients with HIV. Other topic reviews that discuss syphilis include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7584.html" rel="external">
          "Syphilis: Epidemiology, pathophysiology, and clinical manifestations in patients without HIV"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7597.html" rel="external">
          "Syphilis: Treatment and monitoring"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7588.html" rel="external">
          "Syphilis: Screening and diagnostic testing"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7599.html" rel="external">
          "Neurosyphilis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4794.html" rel="external">
          "Syphilis in pregnancy"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/14428.html" rel="external">
          "Congenital syphilis: Clinical manifestations, evaluation, and diagnosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/15400.html" rel="external">
          "Congenital syphilis: Management and outcome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H402717952">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
        </p>
        <p class="headingAnchor" id="H2634659153">
         <span class="h2">
          Overview
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although the rates of primary and secondary syphilis in the United States declined 90 percent from 1990 to 2000, the rates increased annually from 2001 to 2009. From 2005 to 2014, the overall number of reported primary and secondary syphilis cases increased significantly from 8724 to 19,999 [
         <a href="#rid1">
          1,2
         </a>
         ]. By 2018, the overall number of reported primary and secondary syphilis cases was 35,063, which is the highest rate reported since 1993 [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         The rise in the rate of reported syphilis cases is primarily attributable to increased cases among men who have sex with men (MSM). The increasing incidence of syphilis among MSM is due in part to rising rates of risky sexual behaviors, such as anonymous sex, unprotected sex (oral and anal), sex with multiple partners, and/or sex under the influence of drugs, especially methamphetamine [
         <a href="#rid4">
          4-10
         </a>
         ].
        </p>
        <p>
         Syphilis and HIV have similar modes of transmission, and infection with one may enhance the acquisition and transmission of the other. Thus, there is a high rate of HIV coinfection among MSM with syphilis [
         <a href="#rid11">
          11-20
         </a>
         ]. Available data from the United States Centers for Disease Control and Prevention suggest that approximately 42 percent of MSM with primary and secondary syphilis are HIV infected, compared with 8 percent of men who have sex with women and 4 percent of women [
         <a href="#rid3">
          3
         </a>
         ]. In a study that was conducted among United States military personnel, 5.8 percent of 4239 patients with newly diagnosed HIV infection also had serologic evidence of syphilis infection [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3094348361">
         <span class="h2">
          Effect of syphilis on HIV
         </span>
         <span class="headingEndMark">
          —
         </span>
         Genital ulcerative diseases, including primary syphilis, can facilitate both sexual and perinatal HIV transmission [
         <a href="#rid12">
          12,13,21-24
         </a>
         ]. In addition, syphilis can have a negative impact on the immunologic (ie, CD4 count) and virologic status of patients with established HIV infection.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          HIV transmission
         </strong>
         – Several studies have reported an increase in the incidence of HIV infection related to incident syphilis [
         <a href="#rid21">
          21,23,24
         </a>
         ]. This was illustrated in a randomized trial evaluating the efficacy of HIV pre-exposure prophylaxis (PrEP), in which 2499 MSM and transgender women without HIV received
         <a class="drug drug_general" data-topicid="8527" href="/z/d/drug information/8527.html" rel="external">
          tenofovir disoproxil fumarate-emtricitabine
         </a>
         or placebo [
         <a href="#rid21">
          21
         </a>
         ]. Although there was no difference in the syphilis incidence between the study arms, the incidence of HIV was significantly increased in those patients with incident syphilis (8.0 versus 2.8 cases per 100 person-years).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In pregnant women, syphilis may have implications beyond that of congenital syphilis. As an example, maternal syphilis infection was associated with increased risk of mother-to-child transmission of HIV in a study performed in 155 pregnant women in Malawi [
         <a href="#rid22">
          22
         </a>
         ]. Detailed discussions of congenital syphilis and mother-to-child transmission of HIV are found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/14428.html" rel="external">
          "Congenital syphilis: Clinical manifestations, evaluation, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3799.html" rel="external">
          "Prevention of vertical HIV transmission in resource-limited settings"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          HIV parameters
         </strong>
         – Similar to other concomitant infections, such as tuberculosis or herpes simplex, syphilis may have a negative impact on the immunologic and virologic status of a patient with HIV infection [
         <a href="#rid25">
          25-29
         </a>
         ]. As examples:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a hospital-based retrospective study, 282 men with HIV who were subsequently diagnosed with primary or secondary syphilis were compared with 1233 controls without syphilis who were matched for age, sexual orientation, and baseline HIV parameters. Compared with controls, patients with syphilis were more likely to have increases in HIV viral load during the period following a syphilis diagnosis (27.3 versus 16.6 percent), and the viral load increases were of greater magnitude (54,000 versus 11,318 copies/mL) [
         <a href="#rid29">
          29
         </a>
         ]. Syphilis infection was associated with a greater risk of having an increase in viral load, even among men on antiretroviral therapy (ART) with a baseline viral load &lt;500 copies/mL. CD4 cell counts also decreased transiently to a greater degree (mean decline 28 cells/microL) following the syphilis diagnosis, but subsequently returned to baseline levels.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a separate study that included 145 patients with HIV and a detectable plasma viral load, the highest cerebrospinal fluid (CSF) levels of HIV RNA were seen among those who had concurrent neurosyphilis, followed by those with serologic evidence of syphilis (but not neurosyphilis), and those without syphilis coinfection [
         <a href="#rid30">
          30
         </a>
         ]. The authors of this study suggested that syphilis may amplify intrathecal HIV replication, possibly through immune activation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Although any increase in HIV viral load associated with syphilis infection can potentially increase the risk of HIV transmission, the clinical significance of these findings is unclear. In an analysis of prospectively collected information on 2239 persons with HIV (of whom 205 had confirmed syphilis), syphilis did not appear to affect HIV progression, despite transient changes in CD4 counts and viral loads [
         <a href="#rid31">
          31
         </a>
         ]. In addition, there are conflicting data regarding the impact of syphilis on HIV viral load, as no association of early syphilis and changes in blood or semen viral load or CD4 count were found in a retrospective study of 63 patients with HIV and early syphilis [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1455522162">
         <span class="h2">
          Impact of antiretroviral therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several studies suggest that persons with HIV taking potent ART may have better outcomes [
         <a href="#rid32">
          32-35
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study of 231 patients with HIV and syphilis, use of potent ART before diagnosis reduced the odds of neurosyphilis by 65 percent [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study that evaluated treatment outcomes of 110 patients with clinical or serologic evidence of syphilitic meningitis or syphilitic eye disease, 86 (78 percent) were HIV infected [
         <a href="#rid33">
          33
         </a>
         ]. Among those with HIV infection, patients receiving ART were almost four times more likely to have normalization of CSF white blood cells and protein levels and 13 times more likely to have resolution of symptoms compared with those who were not receiving ART.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Retrospective data suggest that immunologic recovery with ART is associated with lower rates of serologic failure [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Additional discussions of ART are found elsewhere. (See
         <a class="local">
          'When to initiate antiretroviral therapy'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/3773.html" rel="external">
          "Selecting antiretroviral regimens for treatment-naïve persons with HIV-1: General approach"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1358159491">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Early in the HIV epidemic, aggressive and atypical clinical presentations of syphilis at each stage were published in case reports and series [
         <a href="#rid36">
          36-38
         </a>
         ]. However, larger case control and cross-sectional studies have suggested that although some differences in clinical manifestations exist among individuals with HIV compared with those without HIV, clinical manifestations are for the most part similar at each stage, regardless of HIV serostatus  (
         <a class="graphic graphic_table graphicRef50435" href="/z/d/graphic/50435.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
         The clinical features that may be unique to patients with HIV are reviewed below. A more detailed discussion of the clinical manifestations seen in patients with syphilis is found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7584.html" rel="external">
          "Syphilis: Epidemiology, pathophysiology, and clinical manifestations in patients without HIV", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3576459565">
         <span class="h2">
          Early syphilis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical manifestations of early syphilis include those associated with primary and secondary disease. The neurologic and ocular manifestations seen in early syphilis are reviewed separately. (See
         <a class="local">
          'Neurologic/ocular syphilis'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1024213132">
         <span class="h3">
          Primary syphilis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The first, or primary, stage of syphilis presents as a chancre, which is typically a painless, clean-based, well-demarcated lesion with firm, indurated margins. Regional lymph nodes tend to enlarge bilaterally, and are described as rubbery and nonpainful. (See
         <a class="medical medical_review" href="/z/d/html/7584.html" rel="external">
          "Syphilis: Epidemiology, pathophysiology, and clinical manifestations in patients without HIV", section on 'Primary syphilis (chancre)'
         </a>
         .)
        </p>
        <p>
         Although chancres are usually solitary, multiple chancres have been described more commonly in persons with HIV compared with those without HIV [
         <a href="#rid40">
          40
         </a>
         ]. In one study that compared 25 patients with HIV to 114 patients without HIV, both the median number of ulcers and the percentage of patients with multiple ulcers were greater among those with HIV [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H949829736">
         <span class="h3">
          Secondary syphilis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Symptoms of secondary syphilis usually occur three to six weeks after the primary stage resolves. Hematogenous dissemination of treponemes early in infection can lead to the diffuse possible findings of secondary syphilis, including dermatologic, neurologic, and ocular manifestations  (
         <a class="graphic graphic_table graphicRef50435" href="/z/d/graphic/50435.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/7584.html" rel="external">
          "Syphilis: Epidemiology, pathophysiology, and clinical manifestations in patients without HIV", section on 'Secondary syphilis'
         </a>
         and
         <a class="local">
          'Neurologic/ocular syphilis'
         </a>
         below.)
        </p>
        <p>
         For the most part, studies comparing patients with HIV and patients without HIV but with secondary syphilis have shown no difference in clinical stage at presentation or in severity of disease [
         <a href="#rid36">
          36,37,41,42
         </a>
         ]. However a few differences have been described. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients with HIV, the early stages of syphilis have been reported to overlap more frequently than in individuals without HIV [
         <a href="#rid36">
          36,37
         </a>
         ]. Specifically, patients with HIV are more likely to have chancres at the same time as they manifest symptoms of secondary syphilis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ulceronodular syphilis (also known as "malignant" lues) is a severe cutaneous form of syphilis  (
         <a class="graphic graphic_picture graphicRef57044" href="/z/d/graphic/57044.html" rel="external">
          picture 1
         </a>
         ), which, although rare, has been described more frequently in patients with HIV [
         <a href="#rid38">
          38,43-46
         </a>
         ]. Defective cell-mediated immunity may play an important role in the pathogenesis of malignant lues [
         <a href="#rid47">
          47
         </a>
         ]. In one case report, skin examination revealed fungating, plaque-like lesions; histology demonstrated a dense, granulomatous, noncaseating infiltrate with plasma cells and histiocytes, absent of or with few spirochetes evident [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Other rare manifestations of secondary syphilis that have been described in both patients with and without HIV include osteitis/periostitis [
         <a href="#rid48">
          48
         </a>
         ], arthritis, glomerulonephritis, hepatitis, and nephrotic syndrome [
         <a href="#rid49">
          49-53
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H684721626">
         <span class="h2">
          Late syphilis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical manifestations of late syphilis (often referred to as tertiary syphilis) include cardiac and gummatous lesions. Patients with late syphilis may also have neurologic findings, which are discussed separately below. (See
         <a class="local">
          'Neurologic/ocular syphilis'
         </a>
         below.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Late benign syphilis or gummatous syphilis
         </strong>
         – The gumma is a granulomatous inflammatory response to a small number of spirochetes. This can occur in any organ system, but the most common sites are in the skeletal, spinal, and mucosal areas.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Central nervous system (CNS) gummas have been reported in individuals with HIV and appear as enhancing lesions on magnetic resonance imaging [
         <a href="#rid54">
          54,55
         </a>
         ]. While gummas generally take 4 to 10 years to develop after initial infection, more rapid progression from the primary chancre to gummatous lesions (eg, over a period of months) has been reported in some patients with HIV [
         <a href="#rid54">
          54
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7584.html" rel="external">
          "Syphilis: Epidemiology, pathophysiology, and clinical manifestations in patients without HIV", section on 'Late syphilis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cardiovascular syphilis
         </strong>
         – Manifestations of cardiovascular syphilis result from an endarteritis obliterans usually involving the vasa vasorum of the aorta. When the ascending aorta is involved, there may also be involvement of the aortic valve ring with aortic regurgitation and coronary artery stenosis. Cases of rapidly developing aortitis have been reported in persons with HIV [
         <a href="#rid56">
          56,57
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7584.html" rel="external">
          "Syphilis: Epidemiology, pathophysiology, and clinical manifestations in patients without HIV", section on 'Late syphilis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7599.html" rel="external">
          "Neurosyphilis", section on 'Late neurosyphilis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H77718130">
         <span class="h2">
          Neurologic/ocular syphilis
         </span>
        </p>
        <p class="headingAnchor" id="H2620789160">
         <span class="h3">
          Neurosyphilis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The term "neurosyphilis" refers to infection of the CNS. Traditionally, patients have been classified as having neurosyphilis only as a late manifestation of the disease. This is inaccurate, however, and neurosyphilis can occur at any time after initial infection.
        </p>
        <p>
         There are many case reports of persons with HIV who have presented with neurosyphilis, and early neurological involvement may be more frequently seen in patients with HIV compared with those who are uninfected [
         <a href="#rid51">
          51,58-70
         </a>
         ]. In a prospective study of 231 individuals with HIV and newly diagnosed syphilis, risk factors for developing neurosyphilis included a CD4 count of &lt;350 cells/microL, a rapid plasma reagin titer &gt;1:128, and male gender [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
         Patients with signs and symptoms of neurosyphilis should undergo a lumbar puncture (LP) to see if there is CNS involvement, as results are used to guide treatment and subsequent monitoring. Patients with neurosyphilis can present with neurologic, ocular, or otic manifestations. The specific clinical manifestations depend upon the stage of disease:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Early neurologic clinical signs and symptoms are usually seen within a few months of infection and may include ophthalmologic (optic neuritis, uveitis), auditory, or cranial nerve abnormalities, as well as acute mental status changes, meningitis, and stroke. Some patients with HIV rapidly progress from early syphilis to clinical neurosyphilis [
         <a href="#rid56">
          56
         </a>
         ], with concomitant symptoms of primary or secondary disease. A more detailed discussion of ocular disease is found below. (See
         <a class="local">
          'Ocular syphilis'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Late neurologic disease is typically seen 10 to 30 years following infection. The most common forms involve the brain and spinal cord parenchyma (general paresis of the insane and tabes dorsalis). (See
         <a class="medical medical_review" href="/z/d/html/7584.html" rel="external">
          "Syphilis: Epidemiology, pathophysiology, and clinical manifestations in patients without HIV", section on 'Central nervous system'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Some patients with neurosyphilis may be asymptomatic. Such patients may have had an LP performed for treatment failure or for evaluation of neurosyphilis in the setting of a high serologic titer and are found to have cerebrospinal fluid (CSF) abnormalities (eg, mononuclear pleocytosis, increased protein concentration, and/or a reactive CSF Venereal Disease Research Laboratory [VDRL] slide test). In one study of 117 patients with HIV diagnosed with neurosyphilis, approximately 33 percent were asymptomatic [
         <a href="#rid58">
          58
         </a>
         ]. A more detailed discussion of how to diagnose neurosyphilis is found below. (See
         <a class="local">
          'Diagnosis of neurosyphilis'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2540300585">
         <span class="h3">
          Ocular syphilis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Syphilis may affect the eye at any stage of the infection. Although ocular syphilis is seen in both individuals with and without HIV, it has been reported more frequently among those with HIV [
         <a href="#rid59">
          59,63-65,67,71,72
         </a>
         ]. As an example, in the United States, an outbreak of ocular syphilis was reported in California and Washington in December 2014; the majority of cases were among HIV-infected men who have sex with men, and several cases resulted in blindness [
         <a href="#rid67">
          67
         </a>
         ]. In a series of 455 patients with HIV and syphilis, 13 percent had ocular syphilis as their primary manifestation [
         <a href="#rid59">
          59
         </a>
         ].
        </p>
        <p>
         Clinical symptoms of ocular syphilis can vary and may include decreased vision, redness, pain, photophobia, and floaters [
         <a href="#rid73">
          73
         </a>
         ]. Ocular findings typically include uveitis or optic neuritis, although syphilis has been documented to affect almost every structure of the eye [
         <a href="#rid74">
          74
         </a>
         ].
        </p>
        <p>
         Ocular syphilis may occur with or without CNS involvement. All patients with ocular syphilis should be treated the same way as those with neurosyphilis; the presence or absence of CNS involvement impacts monitoring after therapy. (See
         <a class="local">
          'Treatment'
         </a>
         below.)
        </p>
        <p>
         In three large studies of ocular syphilis, the majority of patients presented with various symptoms and had posterior uveitis and bilateral eye involvement [
         <a href="#rid62">
          62,74,75
         </a>
         ]. Approximately 10 percent of affected patients had permanent visual impairment [
         <a href="#rid73">
          73,74
         </a>
         ]. In a systematic review of 101 patients with HIV and ocular syphilis, approximately 40 percent presented with only visual symptoms, whereas over half had evidence of a rash consistent with secondary syphilis [
         <a href="#rid76">
          76
         </a>
         ]. Posterior uveitis was significantly more common in individuals with a CD4 count &lt;200 cells/microL. Three patients had a negative nontreponemal test at the time of diagnosis but had evidence of syphilis based upon a positive treponemal test.
        </p>
        <p class="headingAnchor" id="H983131001">
         <span class="h1">
          LATENT SYPHILIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Latent syphilis refers to the period during which patients infected with
         <em>
          Treponema pallidum
         </em>
         have no symptoms but have infection demonstrable by serologic testing. Such patients are usually diagnosed through routine screening. (See
         <a class="local">
          'Screening'
         </a>
         below.)
        </p>
        <p>
         In the United States, this period has classically been separated into two categories:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Early latent syphilis (if infection occurred within the last 12 months)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Late latent syphilis (if infection occurred after 12 months)
        </p>
        <p>
        </p>
        <p>
         It is often not possible to determine when a patient became infected (this is referred to as syphilis of unknown duration), and such individuals should be treated as late latent syphilis cases. A more detailed discussion of latent syphilis is presented elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7584.html" rel="external">
          "Syphilis: Epidemiology, pathophysiology, and clinical manifestations in patients without HIV", section on 'Latent syphilis (asymptomatic)'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3058882047">
         <span class="h1">
          DIAGNOSIS
         </span>
        </p>
        <p class="headingAnchor" id="H2645998750">
         <span class="h2">
          General approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of syphilis is made in the same fashion whether or not an individual is HIV infected. The diagnosis is usually a presumptive one based upon the results of serologic testing (nontreponemal testing such as the rapid plasma reagin [RPR], and treponemal testing such as fluorescent treponemal antibody absorption [FTA-ABS]). (See
         <a class="medical medical_review" href="/z/d/html/7588.html" rel="external">
          "Syphilis: Screening and diagnostic testing", section on 'Serologic testing algorithms'
         </a>
         .)
        </p>
        <p>
         In general, most experts believe that serologic testing for syphilis can be interpreted in the same manner regardless of HIV status. However, on occasion, unusual serologic responses may be seen in persons with HIV who have syphilis [
         <a href="#rid77">
          77
         </a>
         ]. Such responses can include unusually high serologic titers, false-negative tests, and the delayed appearance of seroreactivity [
         <a href="#rid78">
          78-82
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7588.html" rel="external">
          "Syphilis: Screening and diagnostic testing", section on 'Interpretation of serologic testing'
         </a>
         .)
        </p>
        <p>
         Direct methods (eg, darkfield microscopy, direct fluorescent antibody testing), which are used to visualize the organism, are not routinely available in clinical settings because they require special equipment and considerable experience and expertise to properly interpret the results. Thus, for most clinicians, such tests are now viewed as alternative diagnostic tools. However, in some settings (eg, a patient with malignant lues), a biopsy of a skin lesion with requests for silver staining may be useful to confirm the diagnosis [
         <a href="#rid83">
          83
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7588.html" rel="external">
          "Syphilis: Screening and diagnostic testing", section on 'Direct methods for diagnosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1159733180">
         <span class="h2">
          Diagnosis of neurosyphilis
         </span>
        </p>
        <p class="headingAnchor" id="H3421124329">
         <span class="h3">
          Who should be evaluated for neurosyphilis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following groups of patients with HIV should have a lumbar puncture (LP) performed to evaluate for neurosyphilis:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Any patient who is diagnosed with syphilis and has clinical signs or symptoms suggesting neurologic, ocular, or otic involvement [
         <a href="#rid77">
          77
         </a>
         ] (see
         <a class="local">
          'Neurologic/ocular syphilis'
         </a>
         above). Treatment should not be delayed while waiting for the LP results. (See
         <a class="local">
          'Cerebrospinal fluid testing'
         </a>
         below and
         <a class="local">
          'Preferred regimens'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients diagnosed with syphilis who do not have an appropriate clinical or serologic response to initial therapy. (See
         <a class="local">
          'Approach to treatment failure'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         There is controversy as to whether patients with HIV and syphilis should have cerebrospinal fluid (CSF) testing during their initial evaluation if they have no signs or symptoms of neurologic involvement. Our approach, which recommends an LP only in those patients who have neurologic symptoms, is consistent with the 2015 Centers for Disease Control and Prevention sexually transmitted diseases guidelines [
         <a href="#rid77">
          77
         </a>
         ]. Treatment based upon CSF results in the absence of neurologic symptoms has not been associated with improved clinical outcomes. In addition, there are no prospective data assessing the risk of neurosyphilis in patients with early syphilis who have an appropriate decline of RPR titers after
         <a class="drug drug_general" data-topicid="9551" href="/z/d/drug information/9551.html" rel="external">
          benzathine penicillin
         </a>
         treatment.
        </p>
        <p>
         By contrast, other experts (including some UpToDate authors) believe that nearly all patients with HIV and syphilis should have an LP regardless of symptoms, especially those with a CD4 cell count &lt;350 cells/microL and an RPR &gt;1:32 [
         <a href="#rid84">
          84-86
         </a>
         ]. This approach is based in part upon concerns that some patients with HIV may not be able to clear the spirochete from central nervous system (CNS) sites [
         <a href="#rid87">
          87
         </a>
         ]. The rationale for this approach is described in greater detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7599.html" rel="external">
          "Neurosyphilis", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3059341788">
         <span class="h3">
          Cerebrospinal fluid testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         As neurosyphilis is notoriously difficult to diagnosis, clinicians rely on suboptimal indicators of CNS involvement. The diagnosis of neurosyphilis usually depends upon various combinations of reactive serologic test results, an abnormal CSF cell count or protein, and/or a reactive CSF Venereal Disease Research Laboratory (VDRL) test.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The VDRL-CSF is highly specific for neurosyphilis. When this test is reactive in the absence of substantial contamination of CSF with blood, it is considered diagnostic of neurosyphilis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         However, the VDRL-CSF is insensitive; thus, a negative result does not exclude neurosyphilis. Other testing that supports neurosyphilis in a patient with HIV includes:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A CSF cell count &gt;20 cells/microL. This threshold is higher than in patients without HIV infection (in whom a white blood cell count &gt;5 cells/microL is suggestive of neurosyphilis) since patients with HIV infection may have a CSF pleocytosis due to HIV itself [
         <a href="#rid86">
          86
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7599.html" rel="external">
          "Neurosyphilis", section on 'Diagnosis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7588.html" rel="external">
          "Syphilis: Screening and diagnostic testing", section on 'Testing for neurosyphilis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A positive CSF FTA-ABS test, which, although less specific, is highly sensitive for neurosyphilis. Neurosyphilis is highly unlikely with a negative CSF FTA-ABS test. (See
         <a class="medical medical_review" href="/z/d/html/7599.html" rel="external">
          "Neurosyphilis", section on 'Diagnosis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7588.html" rel="external">
          "Syphilis: Screening and diagnostic testing", section on 'Testing for neurosyphilis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          TREATMENT
         </span>
        </p>
        <p class="headingAnchor" id="H3058969432">
         <span class="h2">
          Whom to treat
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients should be treated for syphilis if they have serologic evidence of untreated infection. (See
         <a class="medical medical_review" href="/z/d/html/7588.html" rel="external">
          "Syphilis: Screening and diagnostic testing", section on 'Interpretation of serologic testing'
         </a>
         .)
        </p>
        <p>
         In addition, certain groups of patients should be treated empirically for early syphilis based upon clinical findings (eg, patients with a suspected chancre) or a known recent exposure (presumed incubating syphilis). Patients with primary syphilis may have a negative serologic test early in the course of infection. Empiric treatment is particularly important if a patient is unlikely to follow up. (See
         <a class="local">
          'Early syphilis'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/7597.html" rel="external">
          "Syphilis: Treatment and monitoring", section on 'Treatment after an exposure'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1621502269">
         <span class="h2">
          Treatment regimens
         </span>
        </p>
        <p class="headingAnchor" id="H2706054056">
         <span class="h3">
          Preferred regimens
         </span>
         <span class="headingEndMark">
          —
         </span>
         The patient with HIV and syphilis should be treated with the same regimens as those recommended for HIV-seronegative patients  (
         <a class="graphic graphic_table graphicRef50435" href="/z/d/graphic/50435.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid77">
          77,88
         </a>
         ]. A baseline Venereal Disease Research Laboratory (VDRL) test or rapid plasma reagin (RPR) titer should be drawn on the day of treatment to help with subsequent monitoring. (See
         <a class="local">
          'Response to therapy'
         </a>
         below.)
        </p>
        <p>
         Penicillin is the drug of choice for all stages of syphilis. The specific formulation of penicillin varies with the stage of syphilis. Long-acting
         <a class="drug drug_general" data-topicid="9551" href="/z/d/drug information/9551.html" rel="external">
          benzathine penicillin
         </a>
         given by intramuscular administration can be used for most stages of disease; however, intravenous therapy should be used for the treatment of ocular, otic, and central nervous system disease  (
         <a class="graphic graphic_table graphicRef50435" href="/z/d/graphic/50435.html" rel="external">
          table 1
         </a>
         ). In addition, patients with ocular syphilis should be comanaged with an ophthalmologist.
        </p>
        <p>
         Studies have evaluated alternative dosing regimens (eg, extending or adding additional agents) for individuals with HIV since early data suggested that patients with HIV may be at increased risk for treatment failure and may be more likely to progress to neurosyphilis [
         <a href="#rid42">
          42,56,89
         </a>
         ]. However, available data do
         <strong>
          not
         </strong>
         justify a change in existing treatment recommendations [
         <a href="#rid42">
          42,90-92
         </a>
         ]. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An open-label randomized clinical trial compared the efficacy of single-dose and three-dose regimens of
         <a class="drug drug_general" data-topicid="9551" href="/z/d/drug information/9551.html" rel="external">
          benzathine penicillin
         </a>
         for treatment of early syphilis in 64 individuals with HIV. RPR titers were monitored every three months, and treatment success was defined as a decrease in RPR titers of &gt;2 dilutions during 12-month follow-up [
         <a href="#rid92">
          92
         </a>
         ]. Success rates were 93 percent in single-dose and 100 percent in three-dose arms, with no statistically significant differences between regimens.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In an observational study of 393 cases of early syphilis that occurred among 350 individuals with HIV, patients were treated with
         <a class="drug drug_general" data-topicid="9551" href="/z/d/drug information/9551.html" rel="external">
          benzathine penicillin
         </a>
         ; 141 were treated with a single dose, whereas the others were treated with more than one dose [
         <a href="#rid90">
          90
         </a>
         ]. The vast majority of patients (92 percent) responded to treatment (defined as a ≥fourfold decline in nontreponemal titers at 13 months). The response was not affected by the number of benzathine penicillin doses the patient received (hazard ratio 1.11, 95% CI 0.89-1.4).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A randomized study compared 2.4 million units of
         <a class="drug drug_general" data-topicid="9551" href="/z/d/drug information/9551.html" rel="external">
          benzathine penicillin
         </a>
         alone or with a 10-day course of
         <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">
          amoxicillin
         </a>
         plus
         <a class="drug drug_general" data-topicid="9812" href="/z/d/drug information/9812.html" rel="external">
          probenecid
         </a>
         in patients with early syphilis [
         <a href="#rid42">
          42
         </a>
         ]. There were 541 patients enrolled, including 101 (19 percent) who had HIV infection. Enhanced treatment with amoxicillin and probenecid did not improve response to treatment at one year (ie, a decrease in the RPR titer by two or more dilutions or a change to a nonreactive test), regardless of HIV status.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A retrospective study of 249 patients with early syphilis compared response to therapy (fourfold decrease in VDRL titer 12 months after treatment) of a single- versus a three-dose regimen of
         <a class="drug drug_general" data-topicid="9551" href="/z/d/drug information/9551.html" rel="external">
          benzathine penicillin
         </a>
         [
         <a href="#rid91">
          91
         </a>
         ]. Of the patients evaluated, 84 were HIV infected, and the majority of such patients (80 percent) received treatment with three doses. Although there was a nonsignificant increase in the number of patients with HIV who responded to the three-dose regimen (97 versus 88 percent), higher quality evidence is needed to confirm these findings.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2083868466">
         <span class="h3">
          Alternative regimens
         </span>
         <span class="headingEndMark">
          —
         </span>
         Alternative regimens for the treatment of syphilis primarily include
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         and
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         . The use of these regimens are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7597.html" rel="external">
          "Syphilis: Treatment and monitoring", section on 'Alternative regimens for early syphilis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7597.html" rel="external">
          "Syphilis: Treatment and monitoring"
         </a>
         .)
        </p>
        <p>
         Patients who are treated with one of these alternative agents should be monitored closely since there are limited data on the efficacy of these agents, particularly in patients with HIV [
         <a href="#rid93">
          93-99
         </a>
         ]. Data include a retrospective study of 116 patients with early syphilis (80 percent with HIV infection), in which those who received
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         ,
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         , or
         <a class="drug drug_general" data-topicid="9551" href="/z/d/drug information/9551.html" rel="external">
          penicillin G benzathine
         </a>
         had a similar serologic response [
         <a href="#rid98">
          98
         </a>
         ]. Another study that evaluated 24 patients with HIV and syphilis (primarily early syphilis) also found that ceftriaxone appeared to be a suitable alternative to penicillin [
         <a href="#rid99">
          99
         </a>
         ].
        </p>
        <p>
         Although data on
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         suggest comparable efficacy with
         <a class="drug drug_general" data-topicid="9551" href="/z/d/drug information/9551.html" rel="external">
          penicillin G benzathine
         </a>
         for the treatment of early syphilis [
         <a href="#rid100">
          100,101
         </a>
         ], mutations associated with macrolide resistance appear to be highly prevalent in the United States, Western Europe, and China [
         <a href="#rid102">
          102
         </a>
         ]. Such mutations can also be rapidly induced by the use of azithromycin for syphilis treatment [
         <a href="#rid103">
          103
         </a>
         ]. Thus, macrolides should not be used to treat early syphilis unless other recommended choices are not feasible, and they should be used in consultation with a knowledgeable specialist.
        </p>
        <p class="headingAnchor" id="H1333336109">
         <span class="h2">
          Patient monitoring
         </span>
        </p>
        <p class="headingAnchor" id="H1275127598">
         <span class="h3">
          Jarisch-Herxheimer reaction
         </span>
         <span class="headingEndMark">
          —
         </span>
         The Jarisch-Herxheimer reaction is an acute febrile reaction that usually occurs within the first 24 hours after any therapy for syphilis. HIV coinfection has not been associated with increased or more severe Jarisch-Herxheimer reactions [
         <a href="#rid104">
          104
         </a>
         ]. A more detailed discussion of the Jarisch-Herxheimer reaction is found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7597.html" rel="external">
          "Syphilis: Treatment and monitoring", section on 'Jarisch-Herxheimer reaction'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4277417344">
         <span class="h3">
          Response to therapy
         </span>
        </p>
        <p class="headingAnchor" id="H4035204679">
         <span class="h4">
          Frequency of monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with syphilis should be monitored closely after therapy regardless of their HIV status. However, the frequency of monitoring is greater in patients with HIV compared to those without HIV, as there is concern that patients with HIV infection are at increased risk of treatment failure [
         <a href="#rid42">
          42,89
         </a>
         ].
        </p>
        <p>
         A baseline VDRL or RPR titer should be drawn on the day of treatment. This titer is used for comparison with subsequent titers that are obtained after treatment to assess response. The same nontreponemal test run by the same laboratory is recommended for monitoring response to treatment.
        </p>
        <p>
         The frequency of monitoring varies by stage:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Early syphilis (primary, secondary, and early latent syphilis)
         </strong>
         – Patients with HIV and early syphilis should be evaluated clinically and serologically for treatment failure at 3, 6, 9, 12, and 24 months after therapy [
         <a href="#rid77">
          77
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Late syphilis (tertiary syphilis, late latent syphilis), and latent syphilis of unknown duration
         </strong>
         – In patients with HIV and late syphilis, clinical and serologic follow-up evaluations should be performed at six-month intervals for a two-year period.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Neurosyphilis
         </strong>
         – The approach to cerebrospinal fluid (CSF) monitoring depends upon the presence or absence of a CSF pleocytosis:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In patients with neurosyphilis (including those with ocular or otic syphilis and a CSF pleocytosis or a positive CSF serologic test prior to treatment), CSF examinations should be repeated every six months until the cell count is normal. Resolution of the CSF pleocytosis is the most sensitive indicator of effective treatment in neurosyphilis.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         If the CSF cell count does not normalize, either the CSF protein or CSF-VDRL can be followed. Retreatment is recommended if these parameters do not respond by two years. One study suggested that patients with CD4 counts &lt;200 cells/microL were 3.7 times less likely to normalize CSF-VDRL results than were those patients with higher CD4 cell counts [
         <a href="#rid105">
          105
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In patients with ocular or otic syphilis and a normal CSF examination at the time of initial diagnosis, follow-up lumbar punctures are not needed.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H272288482">
         <span class="h4">
          Expected response
         </span>
         <span class="headingEndMark">
          —
         </span>
         The expected serologic response to therapy depends upon the stage of disease. A fourfold change in titer, equivalent to a change of two dilutions (such as from 1:32 to 1:8), is considered an adequate therapeutic response if documented within a specific time frame:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         6 to 12 months after treatment for early syphilis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         12 to 24 months after treatment for late syphilis and latent syphilis of unknown duration.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The CSF (cell count and VDRL) are expected to normalize within two years after treatment in patients with neurosyphilis (in addition to achieving a serologic response).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Many patients who have an appropriate response to therapy will have complete loss of nontreponemal antibodies; however, some will have antibody titers that remain positive at a low level (ie, serofast). The clinical significance of the serofast state is unclear. At a minimum, these persons should receive additional clinical and serologic follow-up. The approach to patients who do not achieve a fourfold decline in nontreponemal titer, or have an increase in the titer, is discussed below. (See
         <a class="local">
          'Approach to treatment failure'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Studies that have evaluated the association between HIV infection and poor serologic response following syphilis treatment have yielded conflicting results [
         <a href="#rid106">
          106
         </a>
         ]. In one retrospective study that evaluated 129 patients with HIV and 168 patients without HIV but with syphilis attending a sexually transmitted diseases clinic, patients with HIV were less likely to have a fourfold drop in RPR titer and were more likely to take longer to achieve a successful serologic response [
         <a href="#rid89">
          89
         </a>
         ]. Similarly, in a randomized controlled trial of enhanced therapy for early syphilis in patients with and without HIV, patients with HIV and primary and secondary syphilis were more likely than patients without HIV infection to have serologic treatment failure, although clinically defined failure was uncommon in both groups [
         <a href="#rid42">
          42
         </a>
         ]. In this trial, titers declined more slowly in the patients with HIV, particularly those with primary syphilis and those with a previous history of syphilis.
        </p>
        <p>
        </p>
        <p>
         However, the above studies were performed prior to the widespread use of effective combination antiretroviral therapy (ART). Subsequent studies have suggested that the risk of a poor serologic response in the setting of HIV infection may be attenuated by the use of ART or the absence of significant immunosuppression [
         <a href="#rid34">
          34,107
         </a>
         ]. As an example, in a prospective study of 180 patients with HIV who experienced 231 cases of syphilis from 1990 through 2006, a total of 71 episodes of serologic failure were documented [
         <a href="#rid34">
          34
         </a>
         ]. A CD4 count &lt;200 cells/microL at the time of syphilis diagnosis was associated with an increased risk of serologic failure (adjusted hazard ratio [AHR], 2.88; 95% CI 1.26-4.88), whereas receipt of ART was associated with a 60 percent reduction in the rate of serologic failure (AHR, 0.40; 95% CI 0.21-0.75) independent of the CD4 cell response.
        </p>
        <p class="headingAnchor" id="H1392074481">
         <span class="h2">
          Approach to treatment failure
         </span>
         <span class="headingEndMark">
          —
         </span>
         Standard definitions of treatment failure, regardless of HIV status, include: recurrence or persistence of symptoms; lack of a fourfold decrease in nontreponemal test titers at 12 months after treatment for early syphilis or 24 months after treatment of late syphilis or latent syphilis of unknown duration; or a sustained (&gt;2 weeks) fourfold increase in nontreponemal test titers at any time after treatment [
         <a href="#rid77">
          77
         </a>
         ].
        </p>
        <p>
         In some cases, it can be difficult to determine if a patient has failed treatment or has a new infection. Maintaining communication with local or state health departments to verify a patient's latest reported titer and treatment record can assist in further evaluation.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reinfection should be suspected if the patient had an appropriate response to their initial treatment and there is evidence of a new infection (eg, a chancre or rash in the setting of a recent exposure). Such patients can be treated for early syphilis  (
         <a class="graphic graphic_table graphicRef50435" href="/z/d/graphic/50435.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If there is no evidence of new infection, treatment failure should be suspected and a lumbar puncture should be performed to evaluate for neurosyphilis. (See
         <a class="local">
          'Diagnosis of neurosyphilis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         If the CSF examination is normal, treatment with
         <a class="drug drug_general" data-topicid="9551" href="/z/d/drug information/9551.html" rel="external">
          benzathine penicillin
         </a>
         administered as 2.4 million units intramuscularly at weekly intervals for three weeks is recommended [
         <a href="#rid77">
          77
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         If the CSF is abnormal, then treatment for neurosyphilis would be indicated  (
         <a class="graphic graphic_table graphicRef50435" href="/z/d/graphic/50435.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p>
         Antimicrobial regimens used for the treatment of syphilis are discussed in more detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7597.html" rel="external">
          "Syphilis: Treatment and monitoring"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2482578837">
         <span class="h1">
          WHEN TO INITIATE ANTIRETROVIRAL THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many patients with HIV will be on antiretroviral therapy (ART) at the time of their diagnosis. For such patients, ART should be continued, as ART may increase the likelihood that a patient will have an adequate response to therapy. (See
         <a class="local">
          'Response to therapy'
         </a>
         above.)
        </p>
        <p>
         However, certain patients may be diagnosed with HIV at the same time they are diagnosed with syphilis. ART is recommended for all patients with HIV infection regardless of their CD4 count. For such patients, we initiate ART as soon as possible [
         <a href="#rid88">
          88
         </a>
         ]. A discussion of how to select an ART regimen is found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3773.html" rel="external">
          "Selecting antiretroviral regimens for treatment-naïve persons with HIV-1: General approach"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h1">
          SCREENING AND PREVENTION
         </span>
        </p>
        <p class="headingAnchor" id="H469568806">
         <span class="h2">
          Screening
         </span>
         <span class="headingEndMark">
          —
         </span>
         All persons with HIV should be tested for syphilis regardless of symptoms. The approach to syphilis screening in asymptomatic patients is the same for those with and without HIV. (See
         <a class="medical medical_review" href="/z/d/html/7588.html" rel="external">
          "Syphilis: Screening and diagnostic testing"
         </a>
         .)
        </p>
        <p>
         Current recommendations advise that persons with HIV be tested for syphilis upon entry to HIV-related care, on a yearly basis, and more frequently as indicated by ongoing risk behaviors [
         <a href="#rid83">
          83,88,108
         </a>
         ]. Risk behaviors associated with an increased likelihood of becoming infected with syphilis include [
         <a href="#rid109">
          109
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Multiple sex partners
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Anonymous sex partners, including those met through the internet and circuit parties
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Engaging in sex in exchange for drugs or money
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Injection drug use or use of "club drugs"
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H115346979">
         <span class="h2">
          Management after an exposure
         </span>
         <span class="headingEndMark">
          —
         </span>
         Regardless of HIV status, persons exposed sexually to a patient who has syphilis in any stage should be evaluated clinically and serologically. In addition, some patients should be treated empirically for syphilis, regardless of the results of baseline testing. The management of a patient after a known syphilis exposure is presented elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7597.html" rel="external">
          "Syphilis: Treatment and monitoring", section on 'Treatment after an exposure'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2097901894">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/111612.html" rel="external">
          "Society guideline links: Opportunistic infections in adults with HIV"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/111582.html" rel="external">
          "Society guideline links: Sexually transmitted infections"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Syphilis is a sexually acquired infection, which, if left untreated, is characterized by episodes of active clinical disease interrupted by periods of latent infection. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Syphilis can facilitate transmission of HIV. Among men who have sex with men who have syphilis, there is a high rate of HIV coinfection. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The clinical manifestations of syphilis in patients with HIV are generally the same as in those who are HIV uninfected  (
         <a class="graphic graphic_table graphicRef50435" href="/z/d/graphic/50435.html" rel="external">
          table 1
         </a>
         ). However, patients with HIV may be more likely to have multiple chancres and to have chancres present at the same time as symptoms of secondary syphilis. In addition, neurosyphilis may be seen more frequently in patients with HIV infection. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The diagnosis of syphilis is often a presumptive one based upon the results of serologic testing. Direct methods (eg, darkfield microscopy, direct fluorescent antibody testing) are not routinely available in clinical settings because they require special equipment, and the results can be difficult to interpret. (See
         <a class="local">
          'General approach'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Any patient who is diagnosed with syphilis and has clinical signs or symptoms suggesting neurologic, ocular, or otic involvement should be evaluated for neurosyphilis with a lumbar puncture. However, there is controversy as to whether asymptomatic patients with HIV and syphilis require cerebrospinal fluid evaluation. (See
         <a class="local">
          'Diagnosis of neurosyphilis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with HIV and syphilis should be treated with the same regimens as those recommended for HIV-seronegative patients  (
         <a class="graphic graphic_table graphicRef50435" href="/z/d/graphic/50435.html" rel="external">
          table 1
         </a>
         ). However, the frequency of monitoring after treatment is greater in patients with HIV compared to those without HIV, since there is concern that patients with HIV infection are at increased risk of treatment failure. (See
         <a class="local">
          'Treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Certain patients may be diagnosed with HIV at the same time they are diagnosed with syphilis. Antiretroviral therapy is recommended for all patients with HIV infection, regardless of their CD4 count, and should be initiated as soon as possible. (See
         <a class="local">
          'When to initiate antiretroviral therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Persons with HIV should be tested for syphilis (regardless of symptoms) upon entry to HIV care, on a yearly basis, and more frequently as indicated by ongoing risk behaviors. (See
         <a class="local">
          'Screening and prevention'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2014. Atlanta: U.S. Department of Health and Human Services; 2015 http://www.cdc.gov/std/stats14/surv-2014-print.pdf (Accessed on November 23, 2015).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patton ME, Su JR, Nelson R, et al. Primary and secondary syphilis--United States, 2005-2013. MMWR Morb Mortal Wkly Rep 2014; 63:402.
          </a>
         </li>
         <li class="breakAll">
          United States Centers for Disease Control and Prevention. Sexually transmitted disease surveillance, 2018 https://www.cdc.gov/std/stats18/Syphilis.htm (Accessed on October 17, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor MM, Aynalem G, Smith LV, et al. Methamphetamine use and sexual risk behaviours among men who have sex with men diagnosed with early syphilis in Los Angeles County. Int J STD AIDS 2007; 18:93.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control and Prevention (CDC). Methamphetamine use and HIV risk behaviors among heterosexual men--preliminary results from five northern California counties, December 2001-November 2003. MMWR Morb Mortal Wkly Rep 2006; 55:273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spindler HH, Scheer S, Chen SY, et al. Viagra, methamphetamine, and HIV risk: results from a probability sample of MSM, San Francisco. Sex Transm Dis 2007; 34:586.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wong W, Chaw JK, Kent CK, Klausner JD. Risk factors for early syphilis among gay and bisexual men seen in an STD clinic: San Francisco, 2002-2003. Sex Transm Dis 2005; 32:458.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control and Prevention (CDC). Transmission of primary and secondary syphilis by oral sex--Chicago, Illinois, 1998-2002. MMWR Morb Mortal Wkly Rep 2004; 53:966.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thurnheer MC, Weber R, Toutous-Trellu L, et al. Occurrence, risk factors, diagnosis and treatment of syphilis in the prospective observational Swiss HIV Cohort Study. AIDS 2010; 24:1907.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Page-Shafer K, Shiboski CH, Osmond DH, et al. Risk of HIV infection attributable to oral sex among men who have sex with men and in the population of men who have sex with men. AIDS 2002; 16:2350.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ganesan A, Fieberg A, Agan BK, et al. Results of a 25-year longitudinal analysis of the serologic incidence of syphilis in a cohort of HIV-infected patients with unrestricted access to care. Sex Transm Dis 2012; 39:440.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wasserheit JN. Epidemiological synergy. Interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases. Sex Transm Dis 1992; 19:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Røttingen JA, Cameron DW, Garnett GP. A systematic review of the epidemiologic interactions between classic sexually transmitted diseases and HIV: how much really is known? Sex Transm Dis 2001; 28:579.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buchacz K, Klausner JD, Kerndt PR, et al. HIV incidence among men diagnosed with early syphilis in Atlanta, San Francisco, and Los Angeles, 2004 to 2005. J Acquir Immune Defic Syndr 2008; 47:234.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control and Prevention (CDC). Outbreak of syphilis among men who have sex with men--Southern California, 2000. MMWR Morb Mortal Wkly Rep 2001; 50:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control and Prevention (CDC). Primary and secondary syphilis among men who have sex with men--New York City, 2001. MMWR Morb Mortal Wkly Rep 2002; 51:853.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen SY, Gibson S, Katz MH, et al. Continuing increases in sexual risk behavior and sexually transmitted diseases among men who have sex with men: San Francisco, Calif, 1999-2001, USA. Am J Public Health 2002; 92:1387.
          </a>
         </li>
         <li class="breakAll">
          Su JR, Weinstock H. Epidemiology of co-infection with HIV and syphilis in 34 states, United States—2009. In: proceedings of the 2011 National HIV Prevention Conference, August 13–17, 2011, Atlanta, GA.
         </li>
         <li class="breakAll">
          Pathela P, Braunstein S, Shepard CS. Population-based HIV incidence among men diagnosed with infectious syphilis, 2000–2011. In: proceedings of the STI&amp;AIDS World Congress 2013, July 14–17, 2013, Vienna, Austria.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control and Prevention (CDC). Notes from the field: repeat syphilis infection and HIV coinfection among men who have sex with men--Baltimore, Maryland, 2010-2011. MMWR Morb Mortal Wkly Rep 2013; 62:649.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Solomon MM, Mayer KH, Glidden DV, et al. Syphilis predicts HIV incidence among men and transgender women who have sex with men in a preexposure prophylaxis trial. Clin Infect Dis 2014; 59:1020.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mwapasa V, Rogerson SJ, Kwiek JJ, et al. Maternal syphilis infection is associated with increased risk of mother-to-child transmission of HIV in Malawi. AIDS 2006; 20:1869.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reynolds SJ, Risbud AR, Shepherd ME, et al. High rates of syphilis among STI patients are contributing to the spread of HIV-1 in India. Sex Transm Infect 2006; 82:121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spielmann N, Münstermann D, Hagedorn HJ, et al. Time trends of syphilis and HSV-2 co-infection among men who have sex with men in the German HIV-1 seroconverter cohort from 1996-2007. Sex Transm Infect 2010; 86:331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palacios R, Jiménez-Oñate F, Aguilar M, et al. Impact of syphilis infection on HIV viral load and CD4 cell counts in HIV-infected patients. J Acquir Immune Defic Syndr 2007; 44:356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sadiq ST, McSorley J, Copas AJ, et al. The effects of early syphilis on CD4 counts and HIV-1 RNA viral loads in blood and semen. Sex Transm Infect 2005; 81:380.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buchacz K, Patel P, Taylor M, et al. Syphilis increases HIV viral load and decreases CD4 cell counts in HIV-infected patients with new syphilis infections. AIDS 2004; 18:2075.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kofoed K, Gerstoft J, Mathiesen LR, Benfield T. Syphilis and human immunodeficiency virus (HIV)-1 coinfection: influence on CD4 T-cell count, HIV-1 viral load, and treatment response. Sex Transm Dis 2006; 33:143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jarzebowski W, Caumes E, Dupin N, et al. Effect of early syphilis infection on plasma viral load and CD4 cell count in human immunodeficiency virus-infected men: results from the FHDH-ANRS CO4 cohort. Arch Intern Med 2012; 172:1237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Almeida SM, Bhatt A, Riggs PK, et al. Cerebrospinal fluid human immunodeficiency virus viral load in patients with neurosyphilis. J Neurovirol 2010; 16:6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weintrob AC, Gu W, Qin J, et al. Syphilis co-infection does not affect HIV disease progression. Int J STD AIDS 2010; 21:57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghanem KG, Moore RD, Rompalo AM, et al. Neurosyphilis in a clinical cohort of HIV-1-infected patients. AIDS 2008; 22:1145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marra CM, Maxwell CL, Tantalo LC, et al. Normalization of serum rapid plasma reagin titer predicts normalization of cerebrospinal fluid and clinical abnormalities after treatment of neurosyphilis. Clin Infect Dis 2008; 47:893.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghanem KG, Moore RD, Rompalo AM, et al. Antiretroviral therapy is associated with reduced serologic failure rates for syphilis among HIV-infected patients. Clin Infect Dis 2008; 47:258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           González-López JJ, Guerrero ML, Luján R, et al. Factors determining serologic response to treatment in patients with syphilis. Clin Infect Dis 2009; 49:1505.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rompalo AM, Joesoef MR, O'Donnell JA, et al. Clinical manifestations of early syphilis by HIV status and gender: results of the syphilis and HIV study. Sex Transm Dis 2001; 28:158.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rompalo AM, Lawlor J, Seaman P, et al. Modification of syphilitic genital ulcer manifestations by coexistent HIV infection. Sex Transm Dis 2001; 28:448.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schöfer H, Imhof M, Thoma-Greber E, et al. Active syphilis in HIV infection: a multicentre retrospective survey. The German AIDS Study Group (GASG). Genitourin Med 1996; 72:176.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zellan J, Augenbraun M. Syphilis in the HIV-infected patient: an update on epidemiology, diagnosis, and management. Curr HIV/AIDS Rep 2004; 1:142.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           French P. Syphilis. BMJ 2007; 334:143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hutchinson CM, Rompalo AM, Reichart CA, Hook EW 3rd. Characteristics of patients with syphilis attending Baltimore STD clinics. Multiple high-risk subgroups and interactions with human immunodeficiency virus infection. Arch Intern Med 1991; 151:511.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rolfs RT, Joesoef MR, Hendershot EF, et al. A randomized trial of enhanced therapy for early syphilis in patients with and without human immunodeficiency virus infection. The Syphilis and HIV Study Group. N Engl J Med 1997; 337:307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sands M, Markus A. Lues maligna, or ulceronodular syphilis, in a man infected with human immunodeficiency virus: case report and review. Clin Infect Dis 1995; 20:387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yanagisawa N, Imamura A. HIV-positive man with ulceronecrotic skin lesions. Clin Infect Dis 2008; 47:1068.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tucker JD, Shah S, Jarell AD, et al. Lues maligna in early HIV infection case report and review of the literature. Sex Transm Dis 2009; 36:512.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Amico R, Zalusky R. A case of lues maligna in a patient with acquired immunodeficiency syndrome (AIDS). Scand J Infect Dis 2005; 37:697.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Petrozzi JW, Lockshin NA, Berger BJ. Malignant syphilis. Severe variant of secondary syphilis. Arch Dermatol 1974; 109:387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kandelaki G, Kapila R, Fernandes H. Destructive osteomyelitis associated with early secondary syphilis in an HIV-positive patient diagnosed by Treponema pallidum DNA polymerase chain reaction. AIDS Patient Care STDS 2007; 21:229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Colmegna I, Koehler JW, Garry RF, Espinoza LR. Musculoskeletal and autoimmune manifestations of HIV, syphilis and tuberculosis. Curr Opin Rheumatol 2006; 18:88.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coyne K, Browne R, Anagnostopoulos C, Nwokolo N. Syphilitic periostitis in a newly diagnosed HIV-positive man. Int J STD AIDS 2006; 17:421.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaudio PA. Update on ocular syphilis. Curr Opin Ophthalmol 2006; 17:562.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rutland E, Harindra VK. Syphilis: an important cause of infectious hepatitis. Int J STD AIDS 2010; 21:215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Biotti D, Bidot S, Mahy S, et al. Ocular syphilis and HIV infection. Sex Transm Dis 2010; 37:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weinert LS, Scheffel RS, Zoratto G, et al. Cerebral syphilitic gumma in HIV-infected patients: case report and review. Int J STD AIDS 2008; 19:62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hess CW, Rosenfeld SS, Resor SR Jr. Oculomotor nerve palsy as the presenting symptom of gummatous neurosyphilis and human immunodeficiency virus infection: clinical response to treatment. JAMA Neurol 2013; 70:1582.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Musher DM, Hamill RJ, Baughn RE. Effect of human immunodeficiency virus (HIV) infection on the course of syphilis and on the response to treatment. Ann Intern Med 1990; 113:872.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maharajan M, Kumaar GS. Cardiovascular syphilis in HIV infection: a case-control study at the Institute of Sexually Transmitted Diseases, Chennai, India. Sex Transm Infect 2005; 81:361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flood JM, Weinstock HS, Guroy ME, et al. Neurosyphilis during the AIDS epidemic, San Francisco, 1985-1992. J Infect Dis 1998; 177:931.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Balba GP, Kumar PN, James AN, et al. Ocular syphilis in HIV-positive patients receiving highly active antiretroviral therapy. Am J Med 2006; 119:448.e21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oette M, Hemker J, Feldt T, et al. Acute syphilitic blindness in an HIV-positive patient. AIDS Patient Care STDS 2005; 19:209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee JP, Koo SH, Jin SY, Kim TH. Experience of meningovascular syphilis in human immunodeficiency virus infected patient. J Korean Neurosurg Soc 2009; 46:413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li JZ, Tucker JD, Lobo AM, et al. Ocular syphilis among HIV-infected individuals. Clin Infect Dis 2010; 51:468.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uglietti A, Antoniazzi E, Pezzotta S, Maserati R. Syphilitic uveitis as presenting feature of HIV infection in elderly patients. AIDS 2007; 21:535.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shalaby IA, Dunn JP, Semba RD, Jabs DA. Syphilitic uveitis in human immunodeficiency virus-infected patients. Arch Ophthalmol 1997; 115:469.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee SB, Kim KS, Lee WK, et al. Ocular syphilis characterised by severe scleritis in a patient infected with HIV. Lancet Infect Dis 2013; 13:994.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pasricha JM, Read TR, Street AC. Otosyphilis: a cause of hearing loss in adults with HIV. Med J Aust 2010; 193:421.
          </a>
         </li>
         <li class="breakAll">
          Centers for Disease Control and Prevention (CDC). Clinical advisory: ocular syphilis in the United States. www.cdc.gov/std/syphilis/clinicaladvisoryos2015.htm (Accessed on November 08, 2016).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control and Prevention (CDC). Symptomatic early neurosyphilis among HIV-positive men who have sex with men--four cities, United States, January 2002-June 2004. MMWR Morb Mortal Wkly Rep 2007; 56:625.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mishra S, Walmsley SL, Loutfy MR, et al. Otosyphilis in HIV-coinfected individuals: a case series from Toronto, Canada. AIDS Patient Care STDS 2008; 22:213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Firlag-Burkacka E, Swiecki P, Cielniak I, et al. High frequency of neurosyphilis in HIV-positive patients diagnosed with early syphilis. HIV Med 2016; 17:323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kunkel J, Schürmann D, Pleyer U, et al. Ocular syphilis--indicator of previously unknown HIV-infection. J Infect 2009; 58:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oliver SE, Cope AB, Rinsky JL, et al. Increases in ocular syphilis—North Carolina, 2014–2015. Clin Infect Dis 2017.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parc CE, Chahed S, Patel SV, Salmon-Ceron D. Manifestations and treatment of ocular syphilis during an epidemic in France. Sex Transm Dis 2007; 34:553.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moradi A, Salek S, Daniel E, et al. Clinical features and incidence rates of ocular complications in patients with ocular syphilis. Am J Ophthalmol 2015; 159:334.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amaratunge BC, Camuglia JE, Hall AJ. Syphilitic uveitis: a review of clinical manifestations and treatment outcomes of syphilitic uveitis in human immunodeficiency virus-positive and negative patients. Clin Exp Ophthalmol 2010; 38:68.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tucker JD, Li JZ, Robbins GK, et al. Ocular syphilis among HIV-infected patients: a systematic analysis of the literature. Sex Transm Infect 2011; 87:4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Workowski KA, Bolan GA, Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 2015; 64:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Augenbraun MH, DeHovitz JA, Feldman J, et al. Biological false-positive syphilis test results for women infected with human immunodeficiency virus. Clin Infect Dis 1994; 19:1040.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rompalo AM, Cannon RO, Quinn TC, Hook EW 3rd. Association of biologic false-positive reactions for syphilis with human immunodeficiency virus infection. J Infect Dis 1992; 165:1124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hicks CB, Benson PM, Lupton GP, Tramont EC. Seronegative secondary syphilis in a patient infected with the human immunodeficiency virus (HIV) with Kaposi sarcoma. A diagnostic dilemma. Ann Intern Med 1987; 107:492.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tikjøb G, Russel M, Petersen CS, et al. Seronegative secondary syphilis in a patient with AIDS: identification of Treponema pallidum in biopsy specimen. J Am Acad Dermatol 1991; 24:506.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tuddenham S, Obeng C, Ghanem KG. Neurosyphilis and ophthalmic syphilis in persons with negative rapid plasma reagin and positive treponemal antibody test results. Sex Transm Dis 2015; 42:347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control and Prevention (CDC), Health Resources and Services Administration, National Institutes of Health, HIV Medicine Association of the Infectious Diseases Society of America. Incorporating HIV prevention into the medical care of persons living with HIV. Recommendations of CDC, the Health Resources and Services Administration, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2003; 52:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Libois A, De Wit S, Poll B, et al. HIV and syphilis: when to perform a lumbar puncture. Sex Transm Dis 2007; 34:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghanem KG, Moore RD, Rompalo AM, et al. Lumbar puncture in HIV-infected patients with syphilis and no neurologic symptoms. Clin Infect Dis 2009; 48:816.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marra CM, Maxwell CL, Smith SL, et al. Cerebrospinal fluid abnormalities in patients with syphilis: association with clinical and laboratory features. J Infect Dis 2004; 189:369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walter T, Lebouche B, Miailhes P, et al. Symptomatic relapse of neurologic syphilis after benzathine penicillin G therapy for primary or secondary syphilis in HIV-infected patients. Clin Infect Dis 2006; 43:787.
          </a>
         </li>
         <li class="breakAll">
          Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Available at: https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection/whats-new-guidelines (Accessed on July 25, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghanem KG, Erbelding EJ, Wiener ZS, Rompalo AM. Serological response to syphilis treatment in HIV-positive and HIV-negative patients attending sexually transmitted diseases clinics. Sex Transm Infect 2007; 83:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ganesan A, Mesner O, Okulicz JF, et al. A single dose of benzathine penicillin G is as effective as multiple doses of benzathine penicillin G for the treatment of HIV-infected persons with early syphilis. Clin Infect Dis 2015; 60:653.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tittes J, Aichelburg MC, Antoniewicz L, Geusau A. Enhanced therapy for primary and secondary syphilis: a longitudinal retrospective analysis of cure rates and associated factors. Int J STD AIDS 2013; 24:703.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andrade R, Rodriguez-Barradas MC, Yasukawa K, et al. Single Dose Versus 3 Doses of Intramuscular Benzathine Penicillin for Early Syphilis in HIV: A Randomized Clinical Trial. Clin Infect Dis 2017; 64:759.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghanem KG, Erbelding EJ, Cheng WW, Rompalo AM. Doxycycline compared with benzathine penicillin for the treatment of early syphilis. Clin Infect Dis 2006; 42:e45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Long CM, Klausner JD, Leon S, et al. Syphilis treatment and HIV infection in a population-based study of persons at high risk for sexually transmitted disease/HIV infection in Lima, Peru. Sex Transm Dis 2006; 33:151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marra CM, Boutin P, McArthur JC, et al. A pilot study evaluating ceftriaxone and penicillin G as treatment agents for neurosyphilis in human immunodeficiency virus-infected individuals. Clin Infect Dis 2000; 30:540.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wong T, Singh AE, De P. Primary syphilis: serological treatment response to doxycycline/tetracycline versus benzathine penicillin. Am J Med 2008; 121:903.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gutierrez-Galhardo MC, do Valle GF, Sá FC, et al. Clinical characteristics and evolution of syphilis in 24 HIV+ individuals in Rio de Janeiro, Brazil. Rev Inst Med Trop Sao Paulo 2005; 47:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Psomas KC, Brun M, Causse A, et al. Efficacy of ceftriaxone and doxycycline in the treatment of early syphilis. Med Mal Infect 2012; 42:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spornraft-Ragaller P, Abraham S, Lueck C, Meurer M. Response of HIV-infected patients with syphilis to therapy with penicillin or intravenous ceftriaxone. Eur J Med Res 2011; 16:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bai ZG, Wang B, Yang K, et al. Azithromycin versus penicillin G benzathine for early syphilis. Cochrane Database Syst Rev 2012; :CD007270.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hook EW 3rd, Behets F, Van Damme K, et al. A phase III equivalence trial of azithromycin versus benzathine penicillin for treatment of early syphilis. J Infect Dis 2010; 201:1729.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghanem KG. Management of Adult Syphilis: Key Questions to Inform the 2015 Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines. Clin Infect Dis 2015; 61 Suppl 8:S818.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lukehart SA, Godornes C, Molini BJ, et al. Macrolide resistance in Treponema pallidum in the United States and Ireland. N Engl J Med 2004; 351:154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang CJ, Lee NY, Lin YH, et al. Jarisch-Herxheimer reaction after penicillin therapy among patients with syphilis in the era of the hiv infection epidemic: incidence and risk factors. Clin Infect Dis 2010; 51:976.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marra CM, Maxwell CL, Tantalo L, et al. Normalization of cerebrospinal fluid abnormalities after neurosyphilis therapy: does HIV status matter? Clin Infect Dis 2004; 38:1001.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seña AC, Zhang XH, Li T, et al. A systematic review of syphilis serological treatment outcomes in HIV-infected and HIV-uninfected persons: rethinking the significance of serological non-responsiveness and the serofast state after therapy. BMC Infect Dis 2015; 15:479.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Knaute DF, Graf N, Lautenschlager S, et al. Serological response to treatment of syphilis according to disease stage and HIV status. Clin Infect Dis 2012; 55:1615.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen CE, Winston A, Asboe D, et al. Increasing detection of asymptomatic syphilis in HIV patients. Sex Transm Infect 2005; 81:217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control and Prevention (CDC). Primary and secondary syphilis--United States, 2002. MMWR Morb Mortal Wkly Rep 2003; 52:1117.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 7600 Version 21.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://www.cdc.gov/std/stats14/surv-2014-print.pdf" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2014. Atlanta: U.S. Department of Health and Human Services; 2015 http://www.cdc.gov/std/stats14/surv-2014-print.pdf (Accessed on November 23, 2015).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24807239" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Primary and secondary syphilis--United States, 2005-2013.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24807239" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Primary and secondary syphilis--United States, 2005-2013.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17331279" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Methamphetamine use and sexual risk behaviours among men who have sex with men diagnosed with early syphilis in Los Angeles County.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16543881" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Methamphetamine use and HIV risk behaviors among heterosexual men--preliminary results from five northern California counties, December 2001-November 2003.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17334264" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Viagra, methamphetamine, and HIV risk: results from a probability sample of MSM, San Francisco.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15976605" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Risk factors for early syphilis among gay and bisexual men seen in an STD clinic: San Francisco, 2002-2003.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15496825" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Transmission of primary and secondary syphilis by oral sex--Chicago, Illinois, 1998-2002.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20616699" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Occurrence, risk factors, diagnosis and treatment of syphilis in the prospective observational Swiss HIV Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12441814" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Risk of HIV infection attributable to oral sex among men who have sex with men and in the population of men who have sex with men.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22592829" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Results of a 25-year longitudinal analysis of the serologic incidence of syphilis in a cohort of HIV-infected patients with unrestricted access to care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1595015" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Epidemiological synergy. Interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11689757" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : A systematic review of the epidemiologic interactions between classic sexually transmitted diseases and HIV: how much really is known?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18340654" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : HIV incidence among men diagnosed with early syphilis in Atlanta, San Francisco, and Los Angeles, 2004 to 2005.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11393490" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Outbreak of syphilis among men who have sex with men--Southern California, 2000.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12363336" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Primary and secondary syphilis among men who have sex with men--New York City, 2001.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12197957" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Continuing increases in sexual risk behavior and sexually transmitted diseases among men who have sex with men: San Francisco, Calif, 1999-2001, USA.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12197957" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Continuing increases in sexual risk behavior and sexually transmitted diseases among men who have sex with men: San Francisco, Calif, 1999-2001, USA.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12197957" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Continuing increases in sexual risk behavior and sexually transmitted diseases among men who have sex with men: San Francisco, Calif, 1999-2001, USA.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23945772" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Notes from the field: repeat syphilis infection and HIV coinfection among men who have sex with men--Baltimore, Maryland, 2010-2011.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24928295" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Syphilis predicts HIV incidence among men and transgender women who have sex with men in a preexposure prophylaxis trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16954728" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Maternal syphilis infection is associated with increased risk of mother-to-child transmission of HIV in Malawi.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16581736" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : High rates of syphilis among STI patients are contributing to the spread of HIV-1 in India.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20876750" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Time trends of syphilis and HSV-2 co-infection among men who have sex with men in the German HIV-1 seroconverter cohort from 1996-2007.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17159654" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Impact of syphilis infection on HIV viral load and CD4 cell counts in HIV-infected patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16199736" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : The effects of early syphilis on CD4 counts and HIV-1 RNA viral loads in blood and semen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15577629" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Syphilis increases HIV viral load and decreases CD4 cell counts in HIV-infected patients with new syphilis infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16505739" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Syphilis and human immunodeficiency virus (HIV)-1 coinfection: influence on CD4 T-cell count, HIV-1 viral load, and treatment response.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22826097" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Effect of early syphilis infection on plasma viral load and CD4 cell count in human immunodeficiency virus-infected men: results from the FHDH-ANRS CO4 cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20132081" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Cerebrospinal fluid human immunodeficiency virus viral load in patients with neurosyphilis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19933204" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Syphilis co-infection does not affect HIV disease progression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18525260" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Neurosyphilis in a clinical cohort of HIV-1-infected patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18715154" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Normalization of serum rapid plasma reagin titer predicts normalization of cerebrospinal fluid and clinical abnormalities after treatment of neurosyphilis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18532887" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Antiretroviral therapy is associated with reduced serologic failure rates for syphilis among HIV-infected patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19842977" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Factors determining serologic response to treatment in patients with syphilis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11289198" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Clinical manifestations of early syphilis by HIV status and gender: results of the syphilis and HIV study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11473216" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Modification of syphilitic genital ulcer manifestations by coexistent HIV infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8707318" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Active syphilis in HIV infection: a multicentre retrospective survey. The German AIDS Study Group (GASG).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16091235" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Syphilis in the HIV-infected patient: an update on epidemiology, diagnosis, and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17235095" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Syphilis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2001134" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Characteristics of patients with syphilis attending Baltimore STD clinics. Multiple high-risk subgroups and interactions with human immunodeficiency virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9235493" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : A randomized trial of enhanced therapy for early syphilis in patients with and without human immunodeficiency virus infection. The Syphilis and HIV Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7742445" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Lues maligna, or ulceronodular syphilis, in a man infected with human immunodeficiency virus: case report and review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18800931" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : HIV-positive man with ulceronecrotic skin lesions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19455078" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Lues maligna in early HIV infection case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16126575" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : A case of lues maligna in a patient with acquired immunodeficiency syndrome (AIDS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4592567" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Malignant syphilis. Severe variant of secondary syphilis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17461716" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Destructive osteomyelitis associated with early secondary syphilis in an HIV-positive patient diagnosed by Treponema pallidum DNA polymerase chain reaction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16344624" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Musculoskeletal and autoimmune manifestations of HIV, syphilis and tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16734969" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Syphilitic periostitis in a newly diagnosed HIV-positive man.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17065926" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Update on ocular syphilis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20215632" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Syphilis: an important cause of infectious hepatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20118676" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Ocular syphilis and HIV infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18275653" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Cerebral syphilitic gumma in HIV-infected patients: case report and review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24322513" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Oculomotor nerve palsy as the presenting symptom of gummatous neurosyphilis and human immunodeficiency virus infection: clinical response to treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2240901" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Effect of human immunodeficiency virus (HIV) infection on the course of syphilis and on the response to treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16061553" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Cardiovascular syphilis in HIV infection: a case-control study at the Institute of Sexually Transmitted Diseases, Chennai, India.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9534965" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Neurosyphilis during the AIDS epidemic, San Francisco, 1985-1992.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16651059" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Ocular syphilis in HIV-positive patients receiving highly active antiretroviral therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15857191" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Acute syphilitic blindness in an HIV-positive patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19893736" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Experience of meningovascular syphilis in human immunodeficiency virus infected patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20604717" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Ocular syphilis among HIV-infected individuals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17301580" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Syphilitic uveitis as presenting feature of HIV infection in elderly patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9109754" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Syphilitic uveitis in human immunodeficiency virus-infected patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24156900" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Ocular syphilis characterised by severe scleritis in a patient infected with HIV.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20919977" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Otosyphilis: a cause of hearing loss in adults with HIV.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20919977" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Otosyphilis: a cause of hearing loss in adults with HIV.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17597693" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Symptomatic early neurosyphilis among HIV-positive men who have sex with men--four cities, United States, January 2002-June 2004.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18290755" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Otosyphilis in HIV-coinfected individuals: a case series from Toronto, Canada.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27089861" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : High frequency of neurosyphilis in HIV-positive patients diagnosed with early syphilis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19081634" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Ocular syphilis--indicator of previously unknown HIV-infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Increases in ocular syphilis—North Carolina, 2014–2015
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17667532" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Manifestations and treatment of ocular syphilis during an epidemic in France.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25447116" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Clinical features and incidence rates of ocular complications in patients with ocular syphilis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20447104" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Syphilitic uveitis: a review of clinical manifestations and treatment outcomes of syphilitic uveitis in human immunodeficiency virus-positive and negative patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20798396" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Ocular syphilis among HIV-infected patients: a systematic analysis of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26042815" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Sexually transmitted diseases treatment guidelines, 2015.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7888531" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Biological false-positive syphilis test results for women infected with human immunodeficiency virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1583332" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Association of biologic false-positive reactions for syphilis with human immunodeficiency virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3307583" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Seronegative secondary syphilis in a patient infected with the human immunodeficiency virus (HIV) with Kaposi sarcoma. A diagnostic dilemma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2061457" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Seronegative secondary syphilis in a patient with AIDS: identification of Treponema pallidum in biopsy specimen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25970316" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Neurosyphilis and ophthalmic syphilis in persons with negative rapid plasma reagin and positive treponemal antibody test results.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12875251" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Incorporating HIV prevention into the medical care of persons living with HIV. Recommendations of CDC, the Health Resources and Services Administration, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16865051" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : HIV and syphilis: when to perform a lumbar puncture.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19187028" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Lumbar puncture in HIV-infected patients with syphilis and no neurologic symptoms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14745693" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Cerebrospinal fluid abnormalities in patients with syphilis: association with clinical and laboratory features.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16912958" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Symptomatic relapse of neurologic syphilis after benzathine penicillin G therapy for primary or secondary syphilis in HIV-infected patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16912958" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Symptomatic relapse of neurologic syphilis after benzathine penicillin G therapy for primary or secondary syphilis in HIV-infected patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16943224" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Serological response to syphilis treatment in HIV-positive and HIV-negative patients attending sexually transmitted diseases clinics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25389249" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : A single dose of benzathine penicillin G is as effective as multiple doses of benzathine penicillin G for the treatment of HIV-infected persons with early syphilis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24026794" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Enhanced therapy for primary and secondary syphilis: a longitudinal retrospective analysis of cure rates and associated factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28200045" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Single Dose Versus 3 Doses of Intramuscular Benzathine Penicillin for Early Syphilis in HIV: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16477545" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Doxycycline compared with benzathine penicillin for the treatment of early syphilis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16508525" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Syphilis treatment and HIV infection in a population-based study of persons at high risk for sexually transmitted disease/HIV infection in Lima, Peru.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10722441" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : A pilot study evaluating ceftriaxone and penicillin G as treatment agents for neurosyphilis in human immunodeficiency virus-infected individuals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18823862" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Primary syphilis: serological treatment response to doxycycline/tetracycline versus benzathine penicillin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16021289" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Clinical characteristics and evolution of syphilis in 24 HIV+ individuals in Rio de Janeiro, Brazil.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22119040" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Efficacy of ceftriaxone and doxycycline in the treatment of early syphilis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21463980" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Response of HIV-infected patients with syphilis to therapy with penicillin or intravenous ceftriaxone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22696367" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Azithromycin versus penicillin G benzathine for early syphilis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20402591" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : A phase III equivalence trial of azithromycin versus benzathine penicillin for treatment of early syphilis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26602620" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Management of Adult Syphilis: Key Questions to Inform the 2015 Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15247355" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Macrolide resistance in Treponema pallidum in the United States and Ireland.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20825309" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Jarisch-Herxheimer reaction after penicillin therapy among patients with syphilis in the era of the hiv infection epidemic: incidence and risk factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15034833" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Normalization of cerebrospinal fluid abnormalities after neurosyphilis therapy: does HIV status matter?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26511465" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : A systematic review of syphilis serological treatment outcomes in HIV-infected and HIV-uninfected persons: rethinking the significance of serological non-responsiveness and the serofast state after therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22955437" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Serological response to treatment of syphilis according to disease stage and HIV status.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15923288" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Increasing detection of asymptomatic syphilis in HIV patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14627949" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Primary and secondary syphilis--United States, 2002.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
